Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Arctic Bioscience – Christer Valderhaug appointed new CEO

Arctic Bioscience, a biotech company developing and commercializing nutraceutical and pharmaceutical products based on the unique properties of bioactive marine compounds has appointed Christer L. Valderhaug as new CEO.Mr. Valderhaug (49) will join Arctic Bioscience from his position as partner and head of investments at the advisory firm Converto AS based in Ålesund, Norway. Converto supports top management and boards cross a range of industries, including marine growth companies with strategic, operational and financial initiatives to maximize value creation. At Arctic Bioscience, he will

Norway Royal Salmon ASA (NRS) - Mandatory notification of trade

Hatlebrekke Invest AS, close associate to Klaus Hatlebrekke, CEO of Norway Royal Salmon ASA, has today purchased 10,000 shares in Norway Royal Salmon ASA at a price of NOK 158.0281 per share. Ola Loe, CFO of Norway Royal Salmon ASA, has today purchased 10,000 shares in Norway Royal Salmon ASA at a price of NOK 158.0282 per share. Kauna AS, close associate to Anne Sofie, COO Business development of Norway Royal Salmon ASA, has today purchased 1,800 shares in Norway Royal Salmon ASA at a price of NOK 158.0311 per share. This notification has been made pursuant to the Securities

Ylva Sarby Westman leaves her position as deputy CEO and CFO of Castellum

Ylva Sarby Westman has informed the company that she has decided to leave her position as deputy CEO and CFO of Castellum at her own request. She has been employed by Castellum since December 2021 and will remain in her position while the recruitment of a new CFO progresses.The recruitment process for a new CFO begins immediately.   For further information, please contact: Anna-Karin Nyman, Director Communications, Castellum AB, + 46 70 206 75 62, anna-karin.nyman@castellum.se   About Castellum Castellum is one of the largest listed property companies in the Nordic region

ABG Sundal Collier appointed as liquidity provider for Embellence Group

Embellence Group AB (publ) ("Embellence") has entered into an agreement with ABG Sundal Collier ASA ("ABGSC") stating that ABGSC will act as a liquidity provider for the Embellence share. The commitment takes place within the framework of Nasdaq OMX's rules on liquidity providers and means that the liquidity provider quotas the volume of purchases and sales in order to promote the liquidity of the share. The commitment will begin on January 10, 2022.

EnginZyme Selected for Cleantech Group’s 100 List of Companies Committed to Taking Action on the Climate Crisis

Stockholm, Sweden – 13 January 2022: EnginZyme, a leading developer of cell-free biomanufacturing processes, out of over 10,000 entrepreneurs was named a 2022 Global Cleantech 100 Company  by Cleantech Group. The 100 companies on the list represent the private, independent and for-profit companies best positioned to deliver solutions that will take us from commitments to actions in the sprint to net zero.“We are dedicated to solving one of the fundamental challenges

#22-16 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 13.01.2022

United Bankers Plc NOTIFICATION 13.01.2022 at 18:30 UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 13.01.2022 Date 13.01.2022Exchange transaction BuyShare class UNITEDAmount 427Average price/share 14.6500 EURHighest price/share 14.6500 EURLowest price/share 14.6500 EURTotal price 6,255.55 EUR The shares held by United Bankers Plc on 13.01.2022: UNITED 59,543 On behalf of United Bankers Plc  Skandinaviska Enskilda Banken AB (Publ) Antti Salakka         Janne Tiihonen For

ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 13.01.2022

ALEXANDRIA PANKKIIRILIIKE OYJ NOTIFICATION 13.01.2022 at 18:30 EET ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 13.01.2022 Date 13.01.2022Exchange transaction BuyShare class ALEXAmount 120Average price/share 8.9000 EURHighest price/share 8.9000 EURLowest price/share 8.9000 EURTotal price 1,068.00 EUR The shares held by Alexandria Pankkiiriliike Oyj on 13.01.2022: ALEX 48,560 On behalf of Alexandria Pankkiiriliike Oyj  Skandinaviska Enskilda Banken AB (Publ)

#22-15 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

Large international evaluation shows AI accurately diagnoses prostate cancer

Researchers at Karolinska Institutet in Sweden have together with international collaborators completed a comprehensive international validation of artificial intelligence (AI) for diagnosing and grading prostate cancer. The study, published in Nature Medicine, shows that AI systems can identify and grade prostate cancer in tissue samples from different countries equally well as pathologists. The results suggest AI systems are ready to be responsibly introduced as a complementary tool in prostate cancer care, researchers say.The international validation was performed via a competition

Protective gene variant against COVID-19 identified

An international metastudy led by researchers at Karolinska Institutet in Sweden has identified a specific gene variant that protects against severe COVID-19 infection. The researchers managed to pinpoint the variant by studying people of different ancestries, a feat they say highlights the importance of conducting clinical trials that include people of diverse descents. The results are published in the journal Nature Genetics.In addition to old age and certain underlying diseases, genetics can influence whether we become severely affected or only suffer mild illness from COVID-19. Previous

Corem issues green bonds of SEK 2,350 million and announces results from tender offer for the outstanding Klövern 2018/2022 SEK bonds

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR, THE UNITED STATES AND

Nordea to implement an orderly Board Chair succession – Stephen Hester proposed to take over from Torbjörn Magnusson during 2022

Nordea Bank AbpStock exchange release - Inside Information13 January 2022 at 18.00 EET The Shareholders’ Nomination Board of Nordea Bank Abp proposes Stephen Hester as member of the Board of Directors from the next Annual General Meeting of Shareholders and as new Chair of the Board from 1 October 2022 onwards. Torbjörn Magnusson is proposed to continue as Chair of the Board until 30 September 2022 and thereafter as ordinary member of the Board.  The Nomination Board has for the past year worked on Board member recruitment with particular focus on an orderly and successful Board

Resolutions at the extraordinary general meeting in Instalco

At an extraordinary general meeting in Instalco AB (publ) today on 13 January 2022, it was resolved on a share split and amendment of the articles of association.The extraordinary general meeting resolved, in accordance with the board of directors’ proposal, to increase the number of shares in the company by dividing each share into five shares (a so called share split, 5:1). In order to enable the share split, the general meeting resolved to amend § 5 of the company’s articles of association stipulating the minimum and maximum number of shares in such a way that the number of shares in the

Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic obesity disorder

Lund, Sweden — 13 January 2022 — Camurus (NASDAQ STO: CAMX) today announces that the company’s license partner Rhythm Pharmaceuticals has dosed the first patients in a Phase 3 trial evaluating weekly setmelanotide subcutaneous depot in patients six years of age and older with a rare genetic disease of obesity. “We are pleased with the progress of our collaboration with Rhythm and today’s announcement of the first dosing in a randomized controlled Phase 3 trial of our long-acting formulation of setmelanotide in patients with rare genetic obesity disorders.” says Dr. Fredrik Tiberg, CEO

Kap West in Munich chooses WICONA unitised façade solution

Now complete, Kap West provides Munich with a new architectural highlight. This unusual office block in the up-and-coming Am Hirschgarten district is earning praise for its characteristic design and particularly sustainable construction method. Notably, the architects for this LEED Gold-certified high-rise specified a particular WICONA unitised façade construction for the project’s 12,600 m2 façade area. In the suburb of Neuhausen-Nymphenburg, a 7,300 m2 former industrial site (MK8) has been transformed to accommodate forward-looking residential and commercial properties – the new

Newfoundland Tower - A high-performance building using unitised facades

WICONA has designed a high-performance, unitised facade system incorporating two new door innovations for Newfoundland Tower, the tallest residential tower to be built within the Canary Wharf Estate. The manufacturer of highly engineered bespoke systems has developed these solutions to perform well in challenging high-rise conditions. The doors feature unrivalled weather performance, reduced sight lines and are aesthetically pleasing without detracting from the overall design intent of the building.WICONA has designed a high-performance, unitised facade system incorporating two new door

Karo Pharma completes the acquisition of Sylphar International NV

Karo Pharma Aktiebolag (“Karo”) today announces that the previously announced acquisition of the Belgian fast-growing digital-first brand company Sylphar International NV (“Sylphar”) for EUR 290m has been successfully completed according to plan. The transaction is expected to contribute positively to Karo’s market position and further enhance Karo’s strong platform for continued growth, particularly in the digital marketplace. Effective today, Robin List, CEO of Sylphar, shall join the Karo Corporate Management Team, reporting to Christoffer Lorenzen, CEO. Robin shall continue to

BONESUPPORT signs distribution agreement with OrthoPediatrics

Lund, Sweden, 15:30 CET, 22-01-13 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has entered into a distribution agreement with OrthoPediatrics Corp., a leader in the orthopedic pediatric market, to distribute CERAMENT® BONE VOID FILLER (BVF) to pediatric hospitals within the United States. The contract extends BONESUPPORT’s market access further as it provides CERAMENT BVF access to OrthoPediatrics’ network of 250 pediatric hospitals.     In the US, CERAMENT BVF is indicated for use in pediatric patients ages 9

BICO Partners with the Center for Contemporary Sciences to Reduce Animal Testing in Life Sciences

The two organizations will work closely to build support for the bipartisan FDA Modernization Act and reduce animal testing by promoting human-specific medical research technologies that include advanced in-vitro tissue models and 3D bioprinting. Today BICO, a leading bio convergence company, announced a partnership with the Center for Contemporary Sciences (CCS), a research and advocacy organization championing the advancement of human-relevant methodologies in scientific research and drug discovery. Together the two organizations plan to closely align strategy and outreach efforts to

Eco Wave Power and Ocean Power Technologies Announce Collaboration to Propel Wave Energy to the Next Level

13/01/2022- Stockholm, Sweden and Monroe Township, NJ USA - Eco Wave Power Global AB (publ) (Nasdaq First North: ECOWVE and Nasdaq US: WAVE) (“Eco Wave Power”) and Ocean Power Technologies, Inc. (NYSE American: OPTT) (“OPT”), two publicly traded wave energy companies, announced today they are working to utilize their complementary technologies and skills to accelerate wave energy projects pursuant to an agreement previously signed. The companies will work together on several fronts, including knowledge sharing, joint grant submissions, and collaborative assistance in entry to new markets.

Remedy Entertainment Plc: Publishing time for the Financial Statement release 2021

Remedy Entertainment Plc | Press release 16:00 pm (EET) 13 January 2022 Publishing time for the Financial Statement release 2021 Remedy Entertainment Plc will publish its Financial Statement release 2021 on Friday 11 February 2022 at 09:00 am (EET). Remedy will host a webcast and conference call in English on its full year 2021 financial results, including a Q&A session for investors, analysts and media on 11 February 2022, at 11:00 am EET. Remedy’s financial results will be presented by CEO Tero Virtala and CFO Terhi Kauppi. The full year financial report will be available

Kemira Oyj: Proposals of the Nomination Board to the Annual General Meeting 2022

Kemira Oyj, Stock Exchange Release, January 13, 2022 at 4.00 pm (EET)Kemira Oyj: Proposals of the Nomination Board to the Annual General Meeting 2022   The Nomination Board proposes to the Annual General Meeting of Kemira Oyj that eight members (previously seven) be elected to the Board of Directors and that the present members Wolfgang Büchele, Shirley Cunningham, Werner Fuhrmann, Timo Lappalainen, Matti Kähkönen and Kristian Pullola be re-elected as members of the Board of Directors. The Nomination Board proposes that Annika Paasikivi and Tina Sejersgård Fanø be elected as new

There are no items matching the current filter
There are no more items matching the current filter
Back to top